Navigation Links
Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results
Date:8/17/2008

, before fees and expenses, from the issuance in July 2008 of convertible notes and warrants with an additional $4.5 million expected to be received prior to August 25 as agreed to in the July 2008 financing. The Company has also entered into an agreement in July 2008 which makes available an equity line of credit enabling the sale of up to $12 million of common stock over time.

Conference Call Information

On Monday, August 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a quarterly conference call to discuss the company's 2008 second quarter achievements and financial results.

Conference Call Numbers

Monday, August 18

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-800-218-8862 (US Participants)

1-303-262-2191 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11118609#

Live audio webcast at http://www.celltherapeutics.com will be archived for post- listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin, including the risk that the data from the FIT trial may
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... serious infectious diseases, announced today that Jeffrey Riley , ... New York Conference on Thursday, June 27, 2013 at The ... Mr. Riley is scheduled to present at 8:40 a.m. (Eastern ... can be accessed by logging onto the web at ...
(Date:6/19/2013)... WASHINGTON, D.C. (PRWEB) June 19, 2013 ... with its first Bayer Bee Care Community Leadership Award. ... Pollinator Week Congressional Reception in Washington, D.C., an ... pollinators make to the world’s food supply. , ... who have harnessed the power of the honey bee ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Express Diagnostics ... tests, today announced that it has received Class III ... and sell its DrugCheck® NxStep Onsite Drug Screen ... of the rapid screening device in near-patient settings, such ... Screen Cup received Health Canada Class III approval for ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... in early-stage Wisconsin companies topped $100 million last year, but ... interesting investment patterns. , ,The figures were outlined in a ... for 2006, which was produced by NorthStar Economics , ... Department of Financial Institutions . , ,While the total ...
... to add the Olympics to their list of great ... more than just a third-party Wi-Fi agreement. The City ... Wi-Fi and into the real competition of global cities ... Look around, Wi-Fi projects are failing , ,Anyone ...
... This is part II of a two-part column on ... focused on the recent controversy over Avandia, GlaxoSmithKline's diabetes drug. ... be so deeply integral to the system that it might be ... For much of its history, the Food and Drug Administration's ...
Cached Biology Technology:Breaking down Wisconsin's angel capital numbers 2Breaking down Wisconsin's angel capital numbers 3No network infrastructure, no Olympics, no nothing 2No network infrastructure, no Olympics, no nothing 3No network infrastructure, no Olympics, no nothing 4No network infrastructure, no Olympics, no nothing 5No network infrastructure, no Olympics, no nothing 6Reforming FDA: Focus on safety, let market judge efficacy 2Reforming FDA: Focus on safety, let market judge efficacy 3Reforming FDA: Focus on safety, let market judge efficacy 4Reforming FDA: Focus on safety, let market judge efficacy 5Reforming FDA: Focus on safety, let market judge efficacy 6
(Date:6/19/2013)... bred specifically for human consumption qualifies as a gluten-free ... disease (CD), scientists have confirmed in a study published ... . , Joyce Irene Boye and colleagues point ... United States alone have CD. They develop gastrointestinal and ... grains that contain gluten-related proteins. Boye,s team sought to ...
(Date:6/19/2013)... , June 19, 2013  New York College of ... United States Patent and Trademark Office for detecting biometric ... reflect whether guards have been injured, attacked or killed. ... portfolio under the Intellectual Properties Agreements of New York ... , President of New York ...
(Date:6/19/2013)... floods across the Midwest are expected to contribute to ... Mexico "dead zone," according to a University of Michigan ... along with one for the Chesapeake Bay. , The ... Oceanic and Atmospheric Administration, calls for an oxygen-depleted, or ... which would place it among the 10 largest on ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... renews itself may be simpler than what scientists had been ... of The Journal of Biological Chemistry, provides new information on ... significantly affect the way physicians make livers regrow in patients ... , "The human liver is one of the few organs ...
... do it: they simply grab carbon dioxide out of the ... as photosynthesis, the plants use light as their energy source. ... as a carbon source for their synthetic reactions, but it ... Antonietti at the Max Planck Institute for Colloids and Interfaces ...
... inhibitor of a protein that plays key roles in ... the inhibitor can halt the growth of tumors in ... are reported in companion papers reported by two collaborating ... the Research Institute of Molecular Pathology in Vienna, and ...
Cached Biology News:Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3Progress toward artificial photosynthesis? 2New protein inhibitor impedes growth of cancerous cells 2
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: